Guggenheim Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $7.
Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $7.